Omicron-specific boosters near rollout as CDC advisory group signs off

Published September 1, 2022 12:00am ET



<mediadc-video-embed data-state="{"cms.site.owner":{"_ref":"00000161-3486-d333-a9e9-76c6fbf30000","_type":"00000161-3461-dd66-ab67-fd6b93390000"},"cms.content.publishDate":1662039651694,"cms.content.publishUser":{"_ref":"0000017d-fe9d-da96-ad7d-ffbf8a5c0000","_type":"00000161-3461-dd66-ab67-fd6b933a0007"},"cms.content.updateDate":1662039651694,"cms.content.updateUser":{"_ref":"0000017d-fe9d-da96-ad7d-ffbf8a5c0000","_type":"00000161-3461-dd66-ab67-fd6b933a0007"},"rawHtml":"

var _bp = _bp||[]; _bp.push({ "div": "Brid_61970409", "obj": {"id":"27789","width":"16","height":"9","video":"1087729"} }); ","_id":"00000182-f948-d446-af92-fdd969b10000","_type":"2f5a8339-a89a-3738-9cd2-3ddf0c8da574"}”>Video EmbedModerna and Pfizer-BioNTech’s updated COVID-19 booster vaccines that target the highly transmittable omicron variant are expected to be ready for administration in a matter of days after an advisory group for the Centers for Disease Control and Prevention signed off on the updated shots.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.